NASDAQ:CYTK Cytokinetics (CYTK) Stock Price, News & Analysis $56.13 -0.03 (-0.05%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$55.58 -0.56 (-0.99%) As of 11/13/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Cytokinetics Stock (NASDAQ:CYTK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cytokinetics alerts:Sign Up Key Stats Today's Range$55.15▼$56.6650-Day Range$53.69▼$75.3552-Week Range$53.55▼$88.31Volume1.01 million shsAverage Volume2.00 million shsMarket Capitalization$7.82 billionP/E RatioN/ADividend YieldN/APrice Target$106.67Consensus RatingModerate Buy Company Overview Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company’s work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries. Founded in 1997, Cytokinetics is based in South San Francisco, California. Its research has focused on translating advances in muscle biology into potential treatments for serious cardiovascular and other muscle-related diseases.AI Generated. May Contain Errors. Read More Cytokinetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreCYTK MarketRank™: 3.378360655735 of 5 starsCytokinetics scored higher than 68% of companies evaluated by MarketBeat, and ranked 333rd out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on no strong buy ratings, 19 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCytokinetics has a consensus price target of $106.67, representing about 90.0% upside from its current price of $56.13.Amount of Analyst CoverageCytokinetics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cytokinetics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cytokinetics are expected to grow in the coming year, from ($5.85) to ($4.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytokinetics is -9.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytokinetics is -9.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.21% of the float of Cytokinetics has been sold short.Short Interest Ratio / Days to CoverCytokinetics has a short interest ratio ("days to cover") of 14.15, which indicates bearish sentiment.Change versus previous monthShort interest in Cytokinetics has recently decreased by 3.75%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytokinetics does not currently pay a dividend.Dividend GrowthCytokinetics does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment0.81 News SentimentCytokinetics has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Cytokinetics this week, compared to 8 articles on an average week.Search Interest6 people have searched for CYTK on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows2 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,208,290.00 in company stock.Percentage Held by Insiders2.60% of the stock of Cytokinetics is held by insiders.Percentage Held by InstitutionsCytokinetics has minimal institutional ownership at this time.Read more about Cytokinetics' insider trading history. Receive CYTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CYTK Stock News HeadlinesCytokinetics (NASDAQ:CYTK) Director B Lynne Parshall Sells 5,000 Shares of StockNovember 13 at 6:22 AM | insidertrades.comTruist Financial Sticks to Its Buy Rating for Cytokinetics (CYTK)November 12 at 9:28 AM | theglobeandmail.comTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading.November 15 at 1:00 AM | Traders Agency (Ad)Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with ...November 9, 2026 | finance.yahoo.comCytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026November 9, 2026 | globenewswire.comCytokinetics (NASDAQ:CYTK) EVP Sells 3,500 Shares of Company StockNovember 4, 2026 | insidertrades.comInsider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells $471,075.00 in StockNovember 3, 2026 | insidertrades.comCytokinetics (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 3,500 Shares of Company StockOctober 21, 2026 | insidertrades.comSee More Headlines CYTK Stock Analysis - Frequently Asked Questions How have CYTK shares performed this year? Cytokinetics' stock was trading at $63.54 at the start of the year. Since then, CYTK stock has decreased by 11.7% and is now trading at $56.13. How were Cytokinetics' earnings last quarter? Cytokinetics, Incorporated (NASDAQ:CYTK) posted its quarterly earnings data on Wednesday, November, 4th. The biopharmaceutical company reported ($1.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.43) by $0.06. The company's revenue for the quarter was up 2356.5% on a year-over-year basis. Read the conference call transcript. Who are Cytokinetics' major shareholders? Cytokinetics' top institutional shareholders include William Blair Investment Management LLC (1.27%), Pictet Asset Management Holding SA (1.10%), GW&K Investment Management LLC (0.73%) and Fisher Asset Management LLC (0.66%). Insiders that own company stock include Robert I Blum, Fady Ibraham Malik, John T Henderson, Sung Lee, Andrew Callos, Wendell Wierenga, Wendall Wierenga, Muna Bhanji, Robert Arthur Harrington, Robert Wong, Edward M Md Kaye, Robert E Landry and B Lynne Parshall. View institutional ownership trends. How do I buy shares of Cytokinetics? Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cytokinetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cytokinetics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Novavax (NVAX), Tesla (TSLA), Bristol Myers Squibb (BMY), Salesforce (CRM) and Micron Technology (MU). Company Calendar Last Earnings11/04/2026Today11/15/2026UBS Global Biopharma Conference 202611/16/2026Jefferies Global Healthcare Conference11/17/20269th Annual Evercore ISI HealthCONx Conference11/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 10 days, CYTK's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CYTK CIK1061983 Webwww.cytokinetics.com Phone(650) 624-3000Fax650-624-3010Employees673Year Founded1998Price Target and Rating Average Price Target for Cytokinetics$106.67 High Price Target$140.00 Low Price Target$84.00 Potential Upside/Downside+90.0%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage21 Analysts Profitability EPS (Trailing Twelve Months)($6.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$784.96 million Net Margins-686.63% Pretax Margin-686.63% Return on EquityN/A Return on Assets-48.26% Debt Debt-to-Equity RatioN/A Current Ratio3.36 Quick Ratio3.36 Sales & Book Value Annual Sales$88.04 million Price / Sales88.81 Cash FlowN/A Price / Cash FlowN/A Book Value($2.31) per share Price / Book-24.30Miscellaneous Outstanding Shares139,300,000Free Float135,681,000Market Cap$7.82 billion OptionableOptionable Beta0.45 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:CYTK) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.